<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768595</url>
  </required_header>
  <id_info>
    <org_study_id>P2008</org_study_id>
    <nct_id>NCT04768595</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Different Fish Oils on Omega-3 Index (CetoIndex)</brief_title>
  <acronym>CetoIndex</acronym>
  <official_title>A Nutritional, Placebo Controlled, Randomised, Blinded Study of the Effect of Different Fish Oils on Omega-3 Index (CetoIndex)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epax Norway AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Møreforsking AS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Epax Norway AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study determines the EPA DHA uptake from different omega-3 supplements against a control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The chronic uptake of omega-3 fatty acids EPA and DHA are commonly determined by measurement&#xD;
      of EPA and DHA in red bloods cells and presented as a % of total fatty acids, the so-called&#xD;
      Omega-3 Index. The index is a validated risk assessment for cardiovascular disease. Different&#xD;
      fish oils may influence the Omega-3 Index differently depending on their composition. This&#xD;
      study assesses omega-3 commonly found as a supplement vs a fish oil based on north atlantic&#xD;
      fish species.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 3, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Fish oil or placebo are given as gelatin capsules packaged in identical white bottles.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Omega-3 index</measure>
    <time_frame>Baseline (supplementation start: time point 0) to 2 months of supplementation</time_frame>
    <description>Change in the omega-3 index (EPA and DHA content as a % of total fatty acids in red blood cells) from baseline to end of supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in fatty acid profile from baseline to end of supplementation between study arms.</measure>
    <time_frame>Baseline to 2 months of supplementation.</time_frame>
    <description>The secondary endpoint measures the fatty acid profiles from baseline to end of supplementation for each study arm. The results will then be compared between groups. Fatty acid profiles will be analyzed on whole blood samples using the Omega-quant test kit and analysis service. Changes in the analyzed fatty acids are determined from statistical assessment of whole blood analysis. The fatty acid profile is an exploratory endpoint.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1g corn oil capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ceto 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1g capsules containing oil from north atlantic fish containing broad spectrum marine oil.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omega-3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 g capsules containing traditional, commericially available omega-3 marine oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two, 1g capsules taken daily with food</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ceto 10</intervention_name>
    <description>Two, 1g capsules daily with food</description>
    <arm_group_label>Ceto 10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil</intervention_name>
    <description>Two, 1g capsules daily with food</description>
    <arm_group_label>Omega-3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women, ≥18 -65 years of age.&#xD;
&#xD;
          2. Willing to refrain from taking omega-3 supplements for 1 month prior to study start&#xD;
&#xD;
          3. Willing to take study supplement for 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with known allergy to fish products&#xD;
&#xD;
          2. Subjects known to be pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Midtbø, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Møreforsking AS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Derek Tobin, PhD</last_name>
    <email>derek.tobin@pelagia.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Møreforsking AS</name>
      <address>
        <city>Ålesund</city>
        <zip>6006</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Midtbø</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

